Karin Frank-Raue Selected Research

AXT914

1/2014

Amino alcohol- (NPS-2143) and quinazolinone-derived calcilytics (ATF936 and AXT914) differentially mitigate excessive signalling of calcium-sensing receptor mutants causing Bartter syndrome Type 5 and autosomal dominant hypocalcemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Karin Frank-Raue Research Topics

Disease

9	Thyroid Neoplasms (Thyroid Cancer) 10/2021 - 01/2003
9	Neoplasms (Cancer) 01/2018 - 01/2003
5	Neoplasm Metastasis (Metastasis) 10/2021 - 10/2003
5	medullary Thyroid cancer 01/2021 - 11/2009
5	Multiple Endocrine Neoplasia Type 2a (MEN 2) 01/2015 - 01/2007
4	Hyperparathyroidism 11/2016 - 08/2008
3	Nodular Goiter 01/2020 - 01/2018
2	Hyperplasia 01/2018 - 10/2003
2	type 1 familial Hypocalciuric hypercalcemia 11/2016 - 12/2008
2	Lymphatic Metastasis 01/2015 - 11/2009
2	Hypercalciuria 01/2014 - 12/2011
2	Hypocalcemia 01/2014 - 10/2010
2	Primary Hyperparathyroidism 07/2011 - 02/2009
1	Cushing Syndrome 01/2022
1	Residual Neoplasm 10/2021
1	Multiple Endocrine Neoplasia Type 2b (MEN 3) 01/2021
1	Hypothyroidism 01/2019
1	Thyroiditis 01/2018
1	Renal Insufficiency (Renal Failure) 01/2018
1	follicular Thyroid cancer 10/2016
1	Papillary Thyroid Cancer 10/2016
1	Anaplastic Thyroid Carcinoma 10/2016
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2015
1	Thyroid Diseases (Thyroid Disease) 01/2015
1	Bartter Syndrome (Syndrome, Bartter) 01/2014
1	Multiple Endocrine Neoplasia (Multiple Endocrine Adenomatosis) 03/2013
1	Hereditary Neoplastic Syndromes (Cancer Syndrome, Hereditary) 01/2012
1	Hypoparathyroidism 12/2011
1	Nephrocalcinosis 12/2011
1	Pheochromocytoma 08/2008
1	Exanthema (Rash) 08/2007
1	Nausea 08/2007
1	Tachycardia (Tachyarrhythmias) 06/2004
1	Thyroid Hormone Resistance Syndrome (Thyroid Hormone Resistance) 06/2004
1	Vision Disorders (Hemeralopia) 06/2004

Drug/Important Bio-Agent (IBA)

9	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 10/2021 - 01/2007
6	Calcium-Sensing ReceptorsIBA 11/2016 - 12/2008
5	Tumor Biomarkers (Tumor Markers)IBA 10/2021 - 01/2015
4	Codon (Codons)IBA 01/2011 - 10/2003
3	CalciumIBA 11/2016 - 12/2011
2	vandetanib (ZD6474)IBA 01/2021 - 10/2016
2	cabozantinibIBA 01/2021 - 10/2016
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 10/2016 - 01/2012
2	trans-crotonin (CTN)IBA 01/2015 - 01/2015
2	Carcinoembryonic AntigenIBA 01/2015 - 03/2013
1	Phosphotransferases (Kinase)IBA 01/2022
1	ProcalcitoninIBA 10/2021
1	Mitogen-Activated Protein KinasesIBA 01/2021
1	LigandsIBA 01/2021
1	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2019
1	Proton Pump InhibitorsIBA 01/2018
1	RacivirIBA 10/2016
1	Sorafenib (BAY 43-9006)FDA Link 10/2016
1	Thyroglobulin FDA Link 10/2016
1	Indicators and Reagents (Reagents)IBA 01/2015
1	SaltsIBA 01/2014
1	AXT914IBA 01/2014
1	QuinazolinonesIBA 01/2014
1	ATF936IBA 01/2014
1	Sodium Chloride FDA LinkGeneric 01/2014
1	Vitamin D FDA LinkGeneric 12/2011
1	Parathyroid Hormone (Parathormone)IBA 02/2009
1	Imatinib Mesylate (Gleevec)FDA Link 08/2007
1	Thyroid Hormone Receptors beta (TR beta)IBA 06/2004
1	Mutant Proteins (Protein, Mutant)IBA 06/2004
1	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 06/2004
1	Keratin-20 (Cytokeratin 20)IBA 01/2003
1	gastrin-releasing peptide precursorIBA 01/2003

Therapy/Procedure

5	Therapeutics 10/2016 - 08/2007
4	Thyroidectomy 01/2015 - 11/2009
1	Molecular Targeted Therapy 10/2016
1	Precision Medicine 03/2013
1	Parathyroidectomy 02/2009